Huang, Jingcao <br/><br/>
The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells.  [electronic resource] 

 -  Molecular cancer  Nov 2013 
 - 134 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-4598 
<br/><br/><label>Standard No.: </label>10.1186/1476-4598-12-134  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Breast Neoplasms--drug therapy<br/>Cell Line, Tumor<br/>Cyclin-Dependent Kinase Inhibitor p27--metabolism<br/>Drug Resistance, Neoplasm<br/>Drug Synergism<br/>Enzyme Activation<br/>Female<br/>G1 Phase Cell Cycle Checkpoints--drug effects<br/>Humans<br/>Mice<br/>Mice, Nude<br/>Proto-Oncogene Proteins c-akt--metabolism<br/>Receptor, ErbB-3--antagonists & inhibitors<br/>Signal Transduction--drug effects<br/>Trastuzumab<br/>Tumor Burden--drug effects<br/>Xenograft Model Antitumor Assays